Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 13Head & Neck 10Thoracic 8Breast 4Tumor-Agnostic 1Other neoplasm 1

Conditions

Esophageal Malignant Neoplasm, Local Recurrence 1

Interventions

Selenium 4Epoetin Alfa 3Vitamin E 2Darbepoetin alfa 2Aminolevulinic Acid 2venetoclax 1tirbanibulin 1human papillomavirus vaccine, L1 type 16, 18 1fludarabine 1ferrous sulfate 1ferric gluconate 1camrelizumab 1alpha-Tocopherol 1Watchful Waiting 1Vaginal Smears 1Toremifene 1Surveys and Questionnaires 1Sulindac 1Sucrose 1Soybean Proteins 1Rosuvastatin Calcium 1Ropivacaine 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Propofol 1Polymerase Chain Reaction 1Oxycodone 1Ondansetron 1Morphine 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × camrelizumab × Other neoplasm × Clear all
NCT04404491 2020-05-27

Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence

The First Affiliated Hospital of Henan University of Science and Technology

Phase 3 Unknown
240 enrolled
GastrointestinalOther neoplasm

Esophageal Malignant Neoplasm, Local Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡